Deutsche Bank set a €70.00 ($81.40) price objective on Bayer (FRA:BAYN) in a research note released on Wednesday, July 31st, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
BAYN has been the topic of several other research reports. DZ Bank reissued a neutral rating on shares of Bayer in a report on Tuesday, May 14th. JPMorgan Chase & Co. set a €70.00 ($81.40) target price on shares of Bayer and gave the stock a neutral rating in a report on Tuesday, July 30th. Independent Research set a €52.50 ($61.05) target price on shares of Bayer and gave the stock a sell rating in a report on Friday, June 28th. Sanford C. Bernstein set a €90.00 ($104.65) target price on shares of Bayer and gave the stock a buy rating in a report on Tuesday, July 30th. Finally, Warburg Research set a €61.00 ($70.93) target price on shares of Bayer and gave the stock a neutral rating in a report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of €81.43 ($94.69).
FRA:BAYN traded down €1.13 ($1.31) during trading hours on Wednesday, hitting €66.59 ($77.43). 3,337,936 shares of the stock traded hands. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98). The stock has a 50 day moving average price of €60.79 and a 200 day moving average price of €61.00.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Article: Google Finance Portfolio
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.